LT3697795T - (r)-9-(2,5-difluorfenetil)-4-etil-2-metil-1-oksa-4,9-diazaspiro[5.5] undekan-3- ono druskos - Google Patents

(r)-9-(2,5-difluorfenetil)-4-etil-2-metil-1-oksa-4,9-diazaspiro[5.5] undekan-3- ono druskos

Info

Publication number
LT3697795T
LT3697795T LTEPPCT/EP2018/000470T LTEP2018000470T LT3697795T LT 3697795 T LT3697795 T LT 3697795T LT EP2018000470 T LTEP2018000470 T LT EP2018000470T LT 3697795 T LT3697795 T LT 3697795T
Authority
LT
Lithuania
Prior art keywords
difluorophenethyl
undecan
diazaspiro
oxa
salts
Prior art date
Application number
LTEPPCT/EP2018/000470T
Other languages
English (en)
Inventor
Carmen ALMANSA-ROSALES
Nicolas Tesson
Original Assignee
Acondicionamiento Tarrasense
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acondicionamiento Tarrasense filed Critical Acondicionamiento Tarrasense
Publication of LT3697795T publication Critical patent/LT3697795T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
LTEPPCT/EP2018/000470T 2017-10-17 2018-10-16 (r)-9-(2,5-difluorfenetil)-4-etil-2-metil-1-oksa-4,9-diazaspiro[5.5] undekan-3- ono druskos LT3697795T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382695 2017-10-17
PCT/EP2018/000470 WO2019076475A1 (en) 2017-10-17 2018-10-16 (R) -9- (2,5-DIFLUOROPHENETHYL) -4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO SALTS [5.5] UNDECAN-3-ONE

Publications (1)

Publication Number Publication Date
LT3697795T true LT3697795T (lt) 2024-04-10

Family

ID=60201976

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/000470T LT3697795T (lt) 2017-10-17 2018-10-16 (r)-9-(2,5-difluorfenetil)-4-etil-2-metil-1-oksa-4,9-diazaspiro[5.5] undekan-3- ono druskos

Country Status (21)

Country Link
US (1) US11236110B2 (lt)
EP (1) EP3697795B1 (lt)
JP (1) JP2020537648A (lt)
KR (1) KR20200071107A (lt)
CN (1) CN111263764A (lt)
AR (1) AR113770A1 (lt)
AU (1) AU2018353107B2 (lt)
BR (1) BR112020007359A2 (lt)
CA (1) CA3076765A1 (lt)
CO (1) CO2020005710A2 (lt)
DK (1) DK3697795T3 (lt)
FI (1) FI3697795T3 (lt)
IL (1) IL273751B2 (lt)
LT (1) LT3697795T (lt)
MA (1) MA50395A (lt)
MX (1) MX2020004214A (lt)
PH (1) PH12020550104A1 (lt)
PT (1) PT3697795T (lt)
RU (1) RU2020115274A (lt)
SG (1) SG11202002731YA (lt)
WO (1) WO2019076475A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021018824A1 (en) * 2019-07-31 2021-02-04 Esteve Pharmaceuticals, S.A. Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
WO2008105497A1 (ja) 2007-03-01 2008-09-04 Mitsubishi Tanabe Pharma Corporation ベンゾイミダゾール化合物およびその医薬用途
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
WO2009032667A1 (en) 2007-08-29 2009-03-12 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
PL2242759T3 (pl) 2008-02-06 2013-06-28 Astrazeneca Ab Związki
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
MA38569A1 (fr) * 2013-04-23 2017-03-31 Esteve Labor Dr Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物

Also Published As

Publication number Publication date
PT3697795T (pt) 2024-02-29
DK3697795T3 (da) 2024-02-26
AR113770A1 (es) 2020-06-10
RU2020115274A (ru) 2021-11-01
EP3697795B1 (en) 2023-11-22
WO2019076475A1 (en) 2019-04-25
RU2020115274A3 (lt) 2022-04-29
CA3076765A1 (en) 2019-04-25
MX2020004214A (es) 2020-08-13
JP2020537648A (ja) 2020-12-24
IL273751A (en) 2020-05-31
US11236110B2 (en) 2022-02-01
SG11202002731YA (en) 2020-05-28
EP3697795A1 (en) 2020-08-26
BR112020007359A2 (pt) 2020-09-29
PH12020550104A1 (en) 2021-01-25
FI3697795T3 (fi) 2024-02-23
US20200331929A1 (en) 2020-10-22
MA50395A (fr) 2020-08-26
CO2020005710A2 (es) 2020-05-29
IL273751B1 (en) 2023-10-01
CN111263764A (zh) 2020-06-09
AU2018353107A1 (en) 2020-04-23
TW201922752A (zh) 2019-06-16
KR20200071107A (ko) 2020-06-18
IL273751B2 (en) 2024-02-01
AU2018353107B2 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
IL276802A (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones
EP3661918A4 (en) ANALOGUES OF 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE
AU2018258581A8 (en) RAF-degrading conjugate compounds
IL282178A (en) Products, uses and methods
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP4219526A3 (en) Method for preparing amg 416
IL260488B (en) History of 8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane
EP3660019C0 (en) 7H-PYRAZOLO[3,4-D]TRIAZINE-2-OXIDES AS EXPLOSIVES
EP3846791A4 (en) ILLUDIN ANALOGUES, THEIR USES AND PROCEDURES FOR THEIR SYNTHESIS
EP3421444A4 (en) PROCESS FOR PRODUCING 1-CHLORO-2,3,3,3-TETRAFLUOROPROPENE
GB2577981B (en) Methods, products & Uses relating thereto
IL285204A (en) Formulation of apavicin, method for its preparation
GB201813648D0 (en) Methods, products & uses relating thereto
IL273751A (en) Salts of (r)-9-(5,2-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-9,4-diazaspiro[5.5]undecan-3-one
EP3222703B8 (en) Tealight cups, tealights and methods for the production thereof
WO2016145111A3 (en) Methods, systems and kits for enhanced muscle contractile capabilities
GB201817509D0 (en) Products, uses & methods
EP3876894A4 (en) ATTACHED
GB201912016D0 (en) Methods, products & uses relating thereto
GB201815628D0 (en) Belisha beacon
GB201709607D0 (en) The P.I.R. Co. Ltd - business method patent
AU2018901799A0 (en) New synthetic methods
EP3621618A4 (en) TREATMENT OF GASTROPARESIA USING TRIAZASPIRO (4.5) DECANONE
GB201715900D0 (en) Palate-transducers & palate-loudspeakers, new drawings
UA99984U (ru) 8-(4-метилфенил)-6-оксо-3-(4-фторфенил)-3,4-дигидро-2h,6h-пиримидо[2,1-b][1,3,5]тиадиазин-7-карбонитрил